SHPL-49 injection, a new class 1 chemical drug of Shanghai Hutchison Pharmaceuticals, obtained NMPA and FDA clinical trial approval

Shanghai, October 20, 2021/PRNewswire/ - On October 11 and October 18, SHPL-49 injection developed by Shanghai Hehuang Pharmaceutical Co.

Stroke is the second leading cause of death in the world, and it is also the disease with the highest rate of disability in a single disease.

According to the pathological classification, stroke can be divided into ischemic stroke (cerebral ischemic stroke, CIS) and hemorrhagic stroke (cerebralhemorrhagic stroke).

Effective treatment in the acute phase of ischemic stroke (within 2 weeks after the onset) is the key to affecting the prognosis and recovery of patients, but there is a lack of clinically effective drugs for the treatment of acute ischemic stroke

For patients with acute ischemic stroke, the clinical goal is to improve cerebral blood circulation and neuroprotection: protect the ischemic penumbra that has not yet been necrotic, emphasize neuroprotection while thrombolysis, and reduce neurocytopathy caused by ischemia Extent and scope, prolong neuron survival, clinically achieve the purpose of reducing mortality and disability rate, and improving the quality of life

Measures to improve cerebral blood circulation include intravenous thrombolysis, antiplatelet, anticoagulation, defibrillation and other drugs and intravascular treatments (such as intravascular mechanical thrombectomy) to achieve rapid blood flow recovery

In the early stage of SHPL-49, Shanghai University of Traditional Chinese Medicine completed drug discovery and drug-ready research

In March 2019, the patent application materials were transferred to Shanghai Hutchison Pharmaceuticals.

Source: Shanghai Hutchison Pharmaceutical Co.